MORRISTOWN, N.J.—January saw Capsugel announce the completion of its acquisitions of Xcelience and Powdersize, which are now part of the company’s Dosage Form Solutions business unit. The deals were announced on Dec. 14, 2015, though no financial details were disclosed. Capsugel’s Dosage Form Solutions business works to address a variety of product development challenges, such as bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing and inhalation formulation. The acquisitions boost Capsugel’s capabilities in specialized commercial manufacturing, micro-dosing for powder-in-capsule evaluations and particle engineering for enhanced bioavailability, and bring additional infrastructure for handling potent and controlled substances. Guido Driesen, Capsugel president and CEO, said in the original announcement that, “The expertise and high levels of service that we gain in this transaction will make us an even stronger, more differentiated partner as we collaborate with pharmaceutical companies to bring better medicines to patients.”